Bevacizumab Cheaper Than Ranibizumab for Macular Degeneration

by Medscape • 2013/05/23 • 0 Comments

Cost analysis favors one vascular endothelial growth factor inhibitor over another for patients with age-related macular degeneration.
Medscape Medical News

Full Story →

← Aflibercept Therapy for Exudative Age-related Macular Degeneration Resistant to Bevacizumab and Ranibizumab – Corrected Proof

Incidence of Choroidal Neovascularization in the Fellow Eye in the Comparison of Age-Related Macular Degeneration Treatments Trials – Corrected Proof →

Post navigation